↑ トップへ ← 戻る

 Drug(薬物リスト) ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

38 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Abatacept  27件: Abatacept; Abatacept injection; Bms 188667 (abatacept); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept placebo; Abatacept prefilled syringe; Abatacept, rituximab or tocilizumab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Decrease tocilizumab, abatacept; Double-blind abatacept; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; Abatacept subcutaneous; Abatacept sc; Abatacept (aba);   D03203   2件: CD80, CD86   3件: Cell adhesion molecules (CAMs), Intestinal immune network for IgA production, Rheumatoid arthritis   24件:
11,
13,
19,
41,
44,
46,
49,
50,
51,
53,
55,
60,
65,
84,
93,
96,
97,
107,
164,
222,
271,
284,
285,
300
 2   Ademetionine  0件:   D07128   -   -   15件:
6,
14,
22,
43,
44,
46,
47,
49,
50,
60,
84,
93,
96,
97,
172
 3   Ajulemic acid  2件: Ajulemic acid; Resunab, ajulemic acid, anabasum;   D11312   1件: CNR2   1件: Neuroactive ligand-receptor interaction   3件:
50,
51,
299
 4   Alendronic acid  1件: Alendronic acid;   D00939
 D07119 
 1件: FDPS   1件: Terpenoid backbone biosynthesis   7件:
19,
41,
46,
50,
271,
274,
299
 5   Alfacalcidol  3件: Alendronate versus alfacalcidol (1-alpha oh vitamin d); Alfacalcidol; Ibandronate+alfacalcidol+calcium;   D01518   1件: VDR   2件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption   6件:
41,
46,
49,
50,
96,
235
 6   Anakinra  8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra and peg stnf-r1; Kineret® (anakinra); Response to anakinra associated with methotrexate; Anakinra / kineret; Kineret® or anakinra;   D02934   2件: IL1R1, IL1R2   2件: Cytokine-cytokine receptor interaction, Inflammatory mediator regulation of TRP channels   17件:
2,
13,
15,
19,
37,
41,
46,
49,
50,
56,
65,
84,
86,
106,
107,
266,
299
 7   Apremilast  7件: Apremilast; Apremilast 20 mg; Apremilast 30 mg; Apremilast 30mg; Apremilast (cc-10004); Apremilast tablet 20 mg; Apremilast tablet 30 mg bid;   D08860   4件: PDE4A, PDE4B, PDE4C, PDE4D   2件: Purine metabolism, cAMP signaling pathway   5件:
46,
50,
56,
97,
271
 8   Baricitinib  3件: Baricitinib; Baricitinib, olumiant®; Tofacitinib/baricitinib;   D10308   2件: JAK1, JAK2   3件: Chemokine signaling pathway, JAK-STAT signaling pathway, Osteoclast differentiation   8件:
41,
46,
49,
50,
93,
107,
265,
325
 9   Basiliximab  1件: Basiliximab;   D03058   1件: IL2RA   4件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, JAK-STAT signaling pathway   7件:
2,
50,
65,
66,
97,
222,
228
 10   Ciclosporin  7件: Ciclosporin; Ciclosporina; Ciclosporine; Aerolised liposomal ciclosporin a; Ciclosporin (ciclosporinium); Ciclosporin a; Ciclosporine, ciclosporina;   D00184   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   7件: Cellular senescence, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   44件:
11,
14,
19,
20,
26,
28,
36,
38,
39,
40,
41,
42,
45,
46,
49,
50,
53,
55,
56,
58,
60,
61,
62,
63,
64,
65,
90,
95,
97,
113,
162,
164,
222,
223,
226,
228,
234,
269,
274,
283,
284,
285,
302,
326
 11   Corticotropin  10件: Corticotropin; Repository corticotropin injection; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Corticotropin-releasing hormone; Ovine corticotropin-releasing hormone (ocrh); Corticotropin releasing hormone; Repository corticotropin injection -treatment extension; Adrenocorticotropin; Adrenocorticotropin hormone;   D00146   1件: MC2R   3件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Neuroactive ligand-receptor interaction   12件:
2,
13,
46,
49,
50,
66,
75,
78,
84,
145,
193,
222
 12   Creatine  4件: Creatine; Creatine monohydrate; Pyruvate, creatine, niacinamide; Creatine-13c;   -   -   -   12件:
1,
2,
5,
6,
8,
13,
46,
49,
50,
113,
156,
201
 13   Cyclophosphamide  49件: Cyclophosphamide; Cyclophosphamide (drug); Cyclophosphamide and atg; Cyclophosphamide monohydrate; Cyclophosphamide/glatiramer acetate; Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Lenalidomide, dexamethasone and cyclophosphamide; Rituximab and cyclophosphamide iv; Prednisone, cyclophosphamide; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Cyclophosphamide-prednisone-azathioprine; Iv cyclophosphamide; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 50mg; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; Busulfan, cyclophosphamide, atg, gcsf; Campath, fludarabine, cyclophosphamide; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide post transplant; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; High-dose cyclophosphamide; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and steroids; Cyclophosphamide(ctx); Cyclophosphamide + pred; Cyclophosphamide, fludarabine; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Thalidomide, cyclophosphamide and prednisone;   D00287
 D07760 
 -   -   43件:
13,
14,
16,
19,
20,
26,
28,
35,
36,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
52,
56,
60,
61,
62,
65,
66,
84,
85,
93,
96,
162,
164,
172,
222,
224,
265,
274,
283,
284,
285,
288,
326,
331
 14   Denosumab  4件: Denosumab; Pralia 60 mg subcutaneous injection syringe(denosumab); Pralia 60mg subcutaneous injection syringe(denosumab); Denosumab - immunoglobulin g2 human monoclonal antibody to rank ligand;   D03684   1件: TNFSF11   2件: Cytokine-cytokine receptor interaction, Osteoclast differentiation   7件:
46,
50,
93,
95,
96,
274,
299
 15   Etanercept  39件: Etanercept; Enbrel (etanercept); Etanercept 50 mg solution for injection; 50 mg etanercept; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Commercial formulation etanercept; Etanercept (enbrel); Etanercept (enbreltm); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50mg; Etanercept biosimilar; Etanercept liquid; Etanercept or adalimumab; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Methotrexate - etanercept - prednisolone arm; New formulation etanercept; Phase 1: etanercept; Reumatocept (etanercept); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Etanercept, methotrexate, prednisolone; Adalimumab, etanercept, golimumab or infliximab; Etanercept (50mg per week); Etanercept (50mg per week, for 2 weeks); Etanercept (50mg per week, for 4 weeks); Etanercept (full-dose); Etanercept (half-dose); Tapering or discontinuation of etanercept;   D00742   2件: LTA, TNF   9件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   15件:
15,
28,
35,
38,
39,
46,
50,
53,
56,
60,
85,
228,
271,
285,
298
 16   Ethanol  14件: Endocannabinoid palmitoylethanolamide (pea); Palmitoylethanolamide; Treprostinil diethanolamine; Ut-15c (treprostinil diethanolamine); Ut-15c sr (treprostinil diethanolamine); Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; Ethanolamine; Ethanolamine oleate;   D00068
 D02798
 D04855
 D06542 
 -   -   49件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 17   Gevokizumab  2件: Gevokizumab; Gevokizumab open-label;   D09911   1件: IL1B   3件: Cytokine-cytokine receptor interaction, MAPK signaling pathway, NOD-like receptor signaling pathway   4件:
41,
50,
56,
269
 18   Grapefruit  2件: Grapefruit; Grapefruit juice;   -   -   -   5件:
6,
46,
50,
83,
97
 19   Immune Globulin Human  0件:   -   -   -   20件:
2,
11,
13,
14,
17,
18,
35,
38,
39,
43,
45,
49,
50,
51,
63,
65,
85,
164,
296,
309
 20   Infliximab  66件: Infliximab; Infliximab [infliximab biosimilar 3]; Topical infliximab; Remicaide (infliximab); Abp 710 - biosimilar to infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 3 mg/kg; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-eu; Infliximab-pfizer; Innovator infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Intravitreal infliximab; 99m technetium infliximab; 99mtc-infliximab; Inflectra (infliximab); Adalimumab and infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Ct-p13 sc (infliximab); Infliximab (ifx alone); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab 20 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab-biosimilar; Infliximab-innovator; Cyclosporine vs infliximab; Infliximab (ifx); Adalimumab, etanercept, golimumab or infliximab; Infliximab (bcd-055); Infliximab and mtx;   D02598   1件: TNF   9件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   23件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 21   Methimazole  1件: Methimazole;   D00401   1件: TPO   1件: Thyroid hormone synthesis   1件:
50
 22   Methotrexate  81件: Methotrexate; Intrathecal methotrexate; Methotrexate treatment; Mycophenolate mofetil,methotrexate; Methotrexate 2.5 mg; Methotrexate 25 mg; Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Bms-582949 and methotrexate; Certolizumab pegol + methotrexate (mtx); Cp-690,550 + methotrexate; Etanercept + methotrexate; Etanercept , methotrexate; Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate as methotrexate disodium; Methotrexate capsules; Methotrexate disodium; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Methotrexate and folic acid; Methotrexate lachema 5inj. sol; Etanercept, methotrexate, prednisolone; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Azathioprine or methotrexate; Early immunosuppressants (azathioprine, methotrexate); Methotrexate bellon; Methotrexate bellon 25mg/ml; Clobetasol propionate + methotrexate; Treatment with systemic therapy (methotrexate); Cyclosporin, methotrexate (gvhd prophylaxis);   D00142
 D02115 
 2件: DHFR, DHFR2   2件: Folate biosynthesis, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331
 23   Methylprednisolone  29件: Methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Infliximab, methylprednisolone, methotrexate; Methotrexate + methylprednisolone; Administration of rituximab and methylprednisolone; Methylprednisolone (mp); Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Intravenous methylprednisolone; Intravenous (i.v.) methylprednisolone 1000 mg, total 9;   D00407
 D00751
 D00979
 D05000
 D05001
 D05002 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296
 24   Nifedipine  2件: 10% nifedipine cream; Nifedipine;   D00437   4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   4件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction   2件:
50,
81
 25   Nivolumab  1件: Nivolumab;   D10316   1件: PDCD1   3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway   10件:
13,
26,
41,
46,
49,
50,
51,
53,
96,
97
 26   Pirfenidone  6件: Pirfenidone; Pirfenidone and nintedanib; Pirfenidone or nintedanib; Pirfenidoneone; Sub-study: pirfenidone; Pirfenidone 267 mg [esbriet];   D01583   6件: CCL2, IL10, IL1A, IL1B, IL6, TNF   5件: Cellular senescence, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, TGF-beta signaling pathway, TNF signaling pathway   10件:
34,
46,
50,
51,
58,
84,
85,
164,
222,
228
 27   Prednisolone  74件: Prednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methyloprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Peg-liposomal prednisolone sodium phosphate; Prednisolone sodium phosphate; Prednisone/prednisolone; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Intravenous methyl prednisolone; Methyl prednisolone; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; Infliximab, methylprednisolone, methotrexate; Long-circulating liposomal prednisolone; Methotrexate + methylprednisolone; Methotrexate - etanercept - prednisolone arm; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Prednisolone & dipyridamole; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; Corticosteroids (prednisone or prednisolone); Oral prednisolone; Administration of rituximab and methylprednisolone; Prednisolone and taper; Etanercept, methotrexate, prednisolone; Methylprednisolone (mp); Prednisolone + mabthera; Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Prednisone or prednisolone; Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Prednisolone 1mg tablets; Prednisolone 5mg tablet; Glucocorticoid (prednisone or prednisolone); Low dose prednisolone; Medium dose prednisolone; Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Corticosteroid (prednisolone); Prednisolone sodium succinate; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisolone sodium metasulphobenzoate; Prednisolone tablets b.p. 5mg; Intravenous methylprednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil;   D00472
 D00980
 D00981
 D00982
 D01239
 D01998
 D02156
 D03301 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   38件:
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300
 28   Prednisone  59件: Prednisone; Prednisone - azathioprine; Prednisone alone; Granulocyte-colony stimulating factor (g-csf) and prednisone; Prednisone/prednisolone; Prednisone acetate; Prednisone, cyclophosphamide; Over encapsulated prednisone; Prednisone and ustekinumab treatment; Prednisone capsules; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Prednisone (and methylprednisolone); 0 mg prednisone; 5 mg prednisone; Methylprednisone; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Rayos (delayed-release prednisone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide-prednisone-azathioprine; Oral prednisone 5mg; Prednisone discontinuation; Chinese herb prescription granule plus prednisone; Enalapril valsartan methylprednisone; Hormone (prednisone); Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Prednisone + inhibace/cozaar; Prednisone and cyclophosphamide; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Glucocorticoid (prednisone or prednisolone); Hydroxychloroquine + prednisone; Azathioprine/prednisone; 5-asa, prednisone, azathioprine or remicade; 5-aminosalicylic acid(5-asa) and/or prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); Prednisone 0,5 mg/kg orally on alternate days; Prednisone, fk506, mmf; Tacrolimus combined with prednisone; Prednisone acetate tablets; Oral prednisone; Sotatercept with prednisone boost; Prednisone and mycophenolate mofetil; Thalidomide, cyclophosphamide and prednisone;   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   44件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 29   Rituximab  52件: Rituximab; Rituximab (rituxan); Mabthera (rituximab); Mabthera or biosimilar rituximab product; Rituximab infusion; Rituximab it; Rituximab iv; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Rituximab (mabthera® or rituxan®).; Rituximab and cyclophosphamide iv; Rituximab (arm a); Rituximab (arm b); Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Rituxan (inn: rituximab), brand name in the united states; Rituxan® (rituximab); Rituximab - mabthera; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Sait101 (proposed rituximab biosimilar); Individualized dose of rituximab; Rituxan (rituximab); Standard dose of rituximab; Administration of rituximab and methylprednisolone; Rituximab (anti-cd20); Alemtuzumab and rituximab; Bendamustine, rituximab; Mabthera or biosimilar rituximab; Rituximab (mabthera®); Alemtuzumab, rituximab; Dexamethasone and rituximab; Rhtpo in combination with rituximab; Immunosuppressive treatment (eg, rituximab); Rituximab (rtx) and azathioprine (aza); Intravenous rituximab; Combined plasma exchange (pex), rituximab, and corticosteroids; The standard steroid treatment, plasma exchange and rituximab; Rituximab 1g iv; Rituximab combined with omalizumab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Rituximab/ mabthera; Rituximab or rituximab hyaluronidase human;   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331
 30   Sildenafil  25件: Sildenafil; 5% sildenafil cream; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil citrate; Sildenafil therapy; Sildenafil (50 mg); Sildenafil and losartan; 20 mg sildenafil citrate by mouth; Access program - sildenafil citrate, viagra, revatio; Bosentan and sildenafil; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Oral sildenafil; Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil citrate (uk-92,480); Sildenafil singly or in association with bosentan; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Tadalafil and sildenafil; Sildenafil 20 mg tablets; Acute (1 hour) sildenafil; Sildenafil 40mg oral capsule; Sub-chronic (4 weeks) sildenafil;   D02229
 D08514 
 1件: PDE5A   1件: cGMP-PKG signaling pathway   16件:
6,
46,
50,
51,
85,
86,
96,
113,
210,
211,
212,
225,
226,
278,
294,
299
 31   Siponimod  5件: Siponimod; Siponimod 0.25 mg tablet; Siponimod 0.5 mg tablet; Siponimod 1 mg tablet; Siponimod 2 mg tablet;   D11460   2件: S1PR1, S1PR5   2件: Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway   2件:
13,
50
 32   Tacrolimus  13件: Tacrolimus; Tacrolimus capsule; Interferon beta-1b and tacrolimus; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Tacrolimus (prograf®); Tacrolimus with methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Lcp-tacro (tacrolimus); Rectal tacrolimus; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus and mmf; Tacrolimus prolonged-release hard capsules;   D00107
 D08556 
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   7件: Cellular senescence, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   30件:
2,
11,
13,
36,
46,
49,
50,
51,
53,
60,
61,
62,
65,
66,
85,
86,
95,
96,
97,
113,
151,
158,
164,
222,
224,
226,
228,
283,
284,
299
 33   Tocilizumab  26件: Tocilizumab; Tocilizumab injection; Tocilizumab (mra-sc); Corticoids+ tocilizumab 8mg/kg/4 weeks; Tocilizumab + glucocorticoids (gcs); Tocilizumab sc; Tocilizumab treatment; Abatacept, rituximab or tocilizumab; Decrease tocilizumab, abatacept; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab (actemra®); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab prefilled syringe; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; Tocilizumabum; Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Inn-tocilizumab; Tocilizumab infusion roacemtra (eu);   D02596   1件: IL6R   3件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway   16件:
2,
13,
40,
41,
43,
46,
50,
51,
53,
54,
55,
86,
107,
266,
271,
331
 34   Tofacitinib  23件: Chong kun dang tofacitinib tablet; Cp-690,550 (tofacitinib); Tofacitinib; Tofacitinib (xeljanz); Tofacitinib 5 mg; Tofacitinib 5 mg [xeljanz]; Tofacitinib 5mg po bid; Tofacitinib citrate; Tofacitinib citrate (clinical trial image); Tofacitinib citrate (commercial image); Tofacitinib citrate cp-690550; Tofacitinib with methotrexate; Tofacitinib without methotrexate; Tofacitinib/baricitinib; Tofacitinib 5 mg twice daily; Tofacitinib 5mg [xeljanz] 1 year open-label extension; Tofacitinib 5mg oral tablet [xeljanz] 16 week trial; 15n2-tofacitinib; Tofacitinib citrate (proposed commercial formulation – debossed); In double-blind phase: treatment with tofacitinib; In open-label phase: treatment with tofacitinib; Tofacitinib 10 mg; Tofacitinib 2 mg;   D09970   4件: JAK1, JAK2, JAK3, TYK2   2件: Chemokine signaling pathway, JAK-STAT signaling pathway   9件:
46,
49,
50,
51,
84,
96,
97,
107,
271
 35   Topramezone  0件:   -   -   -   7件:
6,
13,
46,
50,
96,
97,
299
 36   Ustekinumab  32件: Ustekinumab; Prednisone and ustekinumab treatment; Ustekinumab (approximately 6 mg/kg); Ustekinumab 90 milligram (mg); Ustekinumab iv; Ustekinumab sc; Ustekinumab 6 mg/kg; Ustekinumab 90 mg; Subcutaneous ustekinumab; Stelara (ustekinumab); Ustekinumab liquid in prefilled syringe; Ustekinumab 180 mg; Ustekinumab 45 mg; Evaluation of biological predictive factors of clinical response to ustekinumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Placebo ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab 130 mg iv; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab sc injection;   D09214   3件: IL12A, IL12B, IL23A   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   16件:
13,
37,
41,
46,
49,
50,
53,
56,
65,
84,
93,
96,
97,
162,
269,
271
 37   Vitamin D  31件: 10000iu vitamin d; 19 nor vitamin d; 25oh-vitamin d; 5000iu vitamin d; Cholecalciferol, vitamin d3; Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Verum arm receiving vitamin d oil; Vitamin d; Vitamin d3; Alendronate versus alfacalcidol (1-alpha oh vitamin d); Vitamin d in arm b; Vitamin d 25(oh)d; Vitamin d3 400 iu; Vitamin d3 6000 iu; Vitamin d3 3000 ui daily; Vitamin d3 4000 ui daily; Vitamin d3 800 ui/day then 800 ui/day; Vitamin d3: 3000 or 4000 ui/day then 2,000 ui/day; High-dose vitamin d (2000 iu per day); Standard-dose vitamin d (400iu per day); Vitamin d 100ug; Vitamin d 10ug; 25-hydroxyvitamin d3; Cholecalciferol (vitamin d3); D6-25-hydroxyvitamin d3; Ergocalciferol (vitamin d2); High-dose vitamin d3; Supplementation with vitamin d2/d3; Vitamin d oil; Vitamin d powder; Vitamin d2;   -   -   -   18件:
13,
19,
41,
46,
49,
50,
68,
93,
95,
96,
98,
179,
222,
228,
235,
274,
298,
299
 38   Yellow Fever Vaccine  2件: Yellow fever vaccine; Yellow fever vaccine (17d);   D06347   -   -   7件:
40,
44,
46,
50,
51,
52,
53

先頭へ